BMS Launches New Auto-Injector for Orencia
Bristol-Myers Squibb (BMS) has launched Orencia (abatacept) ClickJect autoinjector, a new self-administered autoinjector for adults with moderate-to-severe rheumatoid arthritis (RA) that delivers 125 mg of subcutaneous Orencia. Orencia is a biologic that is offered in three administration options: IV infusion, prefilled syringe, and now autoinjector.
Source: BMS